Engineered erythrocytes: influence of P50 rightward shift and oxemia on oxygen transport to tissues

Erythrocytes as Carriers: From Drug Delivery to Biosensors

Drug delivery using natural biological carriers, especially erythrocytes, is a rapidly developing field. Such erythrocytes can act as carriers that prolong the drug's action due to its gradual release from the carrier; as bioreactors with encapsulated enzymes performing the necessary reactions, while remaining inaccessible to the immune system and plasma proteases; or as a tool for targeted drug delivery to target organs, primarily to cells of the reticuloendothelial system, liver and spleen. To date, erythrocytes have been studied as carriers for a wide range of drugs, such as enzymes, antibiotics, anti-inflammatory, antiviral drugs, etc., and for diagnostic purposes (e.g. magnetic resonance imaging). The review focuses only on drugs loaded inside erythrocytes, defines the main lines of research for erythrocytes with bioactive substances, as well as the advantages and limitations of their application. Particular attention is paid to in vivo studies, opening-up the potential for the clinical use of drugs encapsulated into erythrocytes.

Theoretical analysis of effects of blood substitute affinity and cooperativity on organ oxygen transport

Hemoglobin-based O(2) carriers (HBOCs), which are developed as an alternative to blood transfusion, provide O(2) delivery. At present, there is no model to predict the O(2) transport for a red blood cell-HBOC mixture on a whole organ basis. On the basis of the first principles of mass balance, a model of O(2) transport for an organ was derived to calculate venous Po(2) (Pv(O(2))) for a given inlet arterial Po(2) (Pa(O(2))), blood flow, and oxygen consumption. The model was validated by using several in vivo animal studies on HBOC administration for a wide range of HBOC oxygen-binding parameters and predicted Pv(O(2)) for various Pa(O(2)) in the same species. The model was also used to predict the effect of HBOC affinity and cooperativity on Pv(O(2)) for humans. The results indicate that Pv(O(2)) can be increased at a constant blood flow-to-oxygen consumption ratio by reducing the affinity of HBOC for normoxia and mild hypoxia; however, a high-affinity HBOC would be more efficient in maintaining higher Pv(O(2)) for severe hypoxia (Pa(O(2)) < 40 Torr).